"Emerging Fusion Protein Technologies Drive Innovation in Targeted Therapies Across Autoimmune, Cancer, Metabolic, and Cardiovascular Diseases" Boston, Dec. 11, 2025 (GLOBE NEWSWIRE) -- According to ...
Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies. Many ...
Morning Overview on MSN
Study links ZR fusion protein to aggressive pediatric brain tumor growth
A single genetic abnormality found in more than two-thirds of supratentorial ependymomas, a deadly class of pediatric brain tumors, does far more than activate one inflammatory pathway. The ZFTA-RELA ...
BUFFALO, N.Y., — Many childhood cancers start with a hijacking at the molecular level. A group of abnormal proteins known as fusion proteins aberrantly engage with a collection of proteins that ...
A study looking at the biophysical properties of an abnormal protein driving cancer cells is giving scientists new therapeutic clues for how to treat ependymoma, the third most common childhood brain ...
The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...
A team of researchers at Baylor College of Medicine, St. Jude Children’s Research Hospital, Texas Children’s Hospital and ...
The oral molecular glue degrader aims to overcome resistance to standard ALK tyrosine kinase inhibitor therapies.
The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results